Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foundation Medicine Inc.

Bringing genome analysis to routine cancer care

This article was originally published in Start Up

Executive Summary

The wealth of knowledge about genomic alterations that drive cancer has produced a variety of targeted therapies, but when presented with a newly diagnosed patient, oncologists are faced with a wide array of molecular tests to determine which drug might be the best. Foundation Medicine Inc. has developed a fully informative genomic profile that sequences DNA extracted from tumor tissue, identifying variations in over 200 genes that are known to be altered in human solid tumor cancers. The test produces a report that highlights “actionable” genomic alterations and links them to approved drugs known to be effective against the cancer’s genetic profile, or to appropriate clinical trials of targeted therapies in development.

You may also be interested in...



Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn

Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.

Quanticel/Celgene: The Importance Of Linking A Financing And An Exit

Foundation Medicine Seeks "Go-To" Companion Diagnostic Status For Sequencing Test

Foundation says its test service will transition next-generation sequencing from the research bench to routine clinical practice, with the ultimate goal of supplanting the need for individual gene mutation tests to drive oncology drug therapy decisions.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

SC092291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel